Accuray

Accuray Debt

The Debt of Accuray (ARAY) as of Oct 31, 2026 is 183.87 M USD. In the previous year, Debt was 176.38 M USD — a change of 4.25% (higher).

Debt

183.87 MUSD

YoY

4.25%

Last updated:

In 2026, Accuray's total debt was 183.87 M USD, a 4.25% change from the 176.38 M USD total debt recorded in the previous year.

The Accuray Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
159.84 M USD
Jan 1, 2020
221.70 M USD
Jan 1, 2021
199.41 M USD
Jan 1, 2022
199.49 M USD
Jan 1, 2023
205.04 M USD
Jan 1, 2024
210.75 M USD
Jan 1, 2025
176.38 M USD
Jan 1, 2026
183.87 M USD
The Accuray Debt history
YEARDebtYoY
183.87 MUSD+4.25%
176.38 MUSD-16.31%
210.75 MUSD+2.79%
205.04 MUSD+2.78%
199.49 MUSD+0.04%
199.41 MUSD-10.06%
221.70 MUSD+38.70%
159.84 MUSD+21.95%
131.08 MUSD-20.35%
164.57 MUSD-21.79%
210.41 MUSD-47.72%
402.51 MUSD+105.77%
195.61 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accuray Stock analysis

What does Accuray do? Accuray Inc is a company that was founded in 1990 and is headquartered in Sunnyvale, California. It is a global leader in providing precision solutions for the radiation treatment of cancer and other medical conditions. The company aims to develop revolutionary technologies that offer doctors and patients new treatment options for cancer and other diseases. History: Accuray was founded as a start-up company by a group of scientists who believed that cancer treatment was a crucial problem, with a lack of precision and control compromising the effectiveness of treatment. Therefore, they decided to develop a solution focused on precise, non-invasive radiation therapy. Since then, Accuray has continuously developed and introduced innovative technologies to enable better treatment for patients. Business model: Accuray's business model focuses on the development, sale, and service of radiation therapy products and solutions. The company provides global clinical support to ensure that customers receive the best possible application of Accuray technologies. Accuray primarily generates its revenues through the sale of radiation therapy systems and services. The company has over 800 employees worldwide and operates manufacturing locations in the US and China. Products and solutions: Accuray offers a wide range of products and solutions for clinical radiation therapy. These include the TomoTherapy systems, CyberKnife systems, and Radixact systems. The TomoTherapy systems have been specifically designed for precise and patient-specific radiation therapy applications. The technology enables precise dosage of radiation to tumor cells, protecting the surrounding healthy tissues. The CyberKnife system is used for the treatment of tumors that are difficult to access, such as those in the brain or spine. The robotic technology and precise radiation dosage enhance the effectiveness of treatment. With the Radixact system, Accuray offers a system that provides the latest generation of radiation therapy. The system delivers extremely precise dosages to the tumor while maximizing the preservation of surrounding tissues. Divisions: Accuray is divided into three business segments: Oncology Systems, Radiation Therapy Services, and Research Solutions. - Oncology Systems: Accuray offers the aforementioned TomoTherapy, CyberKnife, and Radixact systems, providing customers with the latest technology to treat various types of cancer. - Radiation Therapy Services: Accuray also provides a wide range of service and support offerings for its customers. These services include training, maintenance, technician support, and customer support. - Research Solutions: Accuray's research division provides academic institutions and research laboratories with access to a variety of technologies and solutions for radiation therapy and cancer research. Conclusion: Accuray has tirelessly worked to develop innovative technologies for radiation therapy, enabling better treatment and quality of life for patients. The company has made significant progress in recent years and now offers a wide range of products and solutions to its customers. Accuray has established itself as a global leader in radiation therapy and continues its success story with continuous research and innovation. Answer: Accuray Inc is a company that specializes in providing precision solutions for radiation treatment of cancer and other medical conditions. It was founded in 1990 and is headquartered in Sunnyvale, California. The company aims to develop innovative technologies that offer patients and doctors new treatment possibilities. Accuray has three divisions: Oncology Systems, Radiation Therapy Services, and Research Solutions. Their products include TomoTherapy, CyberKnife, and Radixact systems. Accuray is a leading global provider of radiation therapy solutions and continues to make advancements in research and innovation. Accuray is one of the most popular companies on Eulerpool.

Debt Details

Understanding Accuray's Debt Structure

Accuray's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Accuray's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Accuray’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Accuray’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Accuray stock

Debt of Accuray is 183.87 M USD in 2026.

Debt of Accuray changed from 176.38 M USD to 183.87 M USD, representing a 4.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Accuray since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Accuray historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Accuray

All Key Metrics — Accuray